Skip to main content

Table 5 The Cumulative and Marginal Cost - Effectiveness and Cost – Benefit of SIF in Ottawa Using the Second Model

From: A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Ottawa, Canada

Variables Annual cost of operation Sharing rate #of HIV averted Cost-effectiveness ratio HIV Benefit-cost ratio HIV
Post SIF $2,182,800 11% 7 $311,829 0.68
  ($2,182,800)   (7) ($311,829) (0.68)
Two SIF $4,365,600 8% 13 $335,815 0.63
  ($2,182,800)   (6) ($363,800) (0.6)
Three SIF $6,548,400 6% 16 $409,275 0.51
  ($2,182,800)   (3) ($727,600) (0.3)
Four SIF $8,731,200 5% 18 $485,067 0.43
  ($2,182,800)   (2) ($1,091,400) (0.19)
Five SIF $10,914,000 3% 21 $519,714 0.4
  ($2,182,800)   (3) ($727,600) (0.3)
Six SIF $13,096,800 2% 24 $545,700 0.38
  ($2,182,800)   (3) ($727,600) (0.3)
Seven SIF $15,279,600 1% 27 $565,911 0.37
  ($2,182,800)   (3) ($727,600) (0.3)
  1. Note: The numbers in parentheses represent the marginal results.